La Terapia Ormonale Nel Cancro Della Prostata: Stato Attuale E Prospettive

Murphy G. P. Slack N. H. , Karr J. P. : Natural history, staging and grading of prostatic cancer. In: Javadpour N. : Principles and management of urologic cancer, 2^nd ed., p. 355–365; Williams & Wilkins, Baltimore 1983.

Catalona W. J. , Scott W. W. : Carcinoma of the prostate: a review. J. Urol, 119; 1 (1978).

Enstrom J. E. , Austin D. F. : Interpreting cancer survival rates. Science, 195; 847 (1977).

Whitmore W. F. jr. : Natural history and staging of prostate cancer. Urol. Clin. N. Amer., 11; 205 (1984).

Klein L. A. : Prostatic caricnoma. N. Engl. J. Med., 300; 824 (1979).

Mellinger G. T. , Bailar J. D. III , Arduino L. J. : Treatment and survival of patients with cancer of the prostate. Surg., Gynec. & Obst., 124; 1011 (1967).

Murphy G. P. , Natarajan N. , Pontes J. E. : The national survey of prostate cancer in the United States by the American College of Surgeons. J. Urol., 127; 928 (1982).

Huggins C. , Hodges C. V. : Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1; 293 (1941).

Gutman E. B. , Sproul E. E. , Gutman A. B. : Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Amer. J. Cancer, 28; 485 (1936).

Scott W. W. , Menon M. , Walsh P. C. : Hormonal therapy of prostatic cancer. Cancer, 45 (suppl.); 1929 (1980).

De Jong F. H. : Secretion and production of androgens. In: Schroeder F. H. (ed.): Androgens and anti-androgens. Intern. Symposium, June 5^th, 1982, p. 5–14; Schering Nederland BV, Arnheim 1983.

Bartsch G. , Rohr H. P. : Endocrinological basis and clinical experience in conservative therapy in benign prostatic hyper plasia. In: Schroeder F. H. (ed.), op. cit., p. 69–91 (1983).

Keenan E. J. , Kemp E. D. , Ramsey E. E. : Specific binding of prolactin by the prostate gland of the rat and man. J. Urol., 122; 43 (1979).

Shearer R. J. , Hendry W. F. , Sommerville I. F. , Fergusson J. D. : Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Brit. J. Urol., 45; 668 (1973).

Peeling B. : Castration for prostatic carcinoma is still an alternative form of treatment? In: Schroeder F. H. (ed.), op cit., p. 125–129 (1983).

Sanford E. J. , Paulson D. F. , Rohner T. J. : The effect of castration on adrenal testosterone secretion in men with prostatic carcinoma. J. Urol., 118; 1019 (1977).

Walsh P. C. , Siiteri P. K. : Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J. Urol., 114; 254 (1975).

Harper M. E. , Peeling W. B. , Cowley T. : Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol., 81; 409 (1976).

Jones T. M. , Fang V. S. , Landau R. L. , Rosenfield R. : Direct inhibition of Leydig cell function by estradiol. J. Clin. Endocrinol. Metab., 47; 1368 (1979).

Farnsworth W. E. : A direct effect of estrogen on prostatic metabolism of testosterone. Invest. Urol., 6; 423 (1969).

Moore R. J. , Gazak J. M. , Wilson J. D. : Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17-β estradiol. J. Clin. Invest., 63; 351 (1979).

Altwein J. E. : Cardiovascular side effects of endocrine management of prostatic carcinoma. In: Schroeder F. H. (ed.), op cit., p. 133–146 (1983).

Varenhorst E. , Wallentin L. , Risberg B. : The effects of orchiectomy, oestrogens and cyproterone acetate on the antithrombin III concentration in carcinoma of the prostate. Urol. Res., 9; 25 (1981).

Byar D. P. : The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer, 32; 1126 (1973).

Blackard C. E. : The Veterans Administration Cooperative Urological Research Group's studies of carcinoma of the prostate: a review. Cancer Chemother. Rep., 59; 225 (1975).

Menon M. , Walsh P. C. : Hormonal therapy for prostatic cancer. In: Murphy G. P. (ed.): Prostatic Cancer, p. 175–200. P.C.G. Publishing Co., Littleton, Massachussets 1979.

Jacobi B. H. , Altwein J. E. , Kurth K. H. : Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Brit. J. Urol., 52; 208 (1980).

Susan L. P. , Roth B. R. , Adkins W. C. : Regression of prostatic cancer metastases by high doses of diethylstilbestrol diphosphate. Urology, 7; 598 (1976).

De Voogt H. J. , Pavone Mscaluso M. : Final analysis of E.O.R.T.C. Trial 30761 concerning treatment of advanced prostatic cancer with different antiandrogenic hormones. A.U.A. 79^th Annual Meeting (Abstr. N° 411). J. Urol, 131; 206 (1984).

Smith R. B. , Walsh P. C. , Goodwin W. E. : Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J. Urol., 110; 106 (1973).

Tunn U. W. , Graff J. , Senge T. H. , Treatment of inoperable prostatic cancer with cyproterone acetate. In: Schroeder F. H. (ed.), op. cit., p. 149–159 (1983).

Stoliar B. , Albert D. J. : Sch 13521 in the treatment of advanced carcinoma of the prostate. J. Urol., 111; 803 (1974).

Sogani P. C. , Whitmore W. R. : Experience with flutamide in previously untreated patients with advanced prostatic cancer. J. Urol., 122; 640 (1979).

Labrie F. , Dupont A. , Belanger A. : Dramatic response of prostate cancer to complete antihormonal treatment. In: Bracci U. , Di Silverio F. (eds.), Advances in urological oncology and endocrinology. Proceedings of the 3^rd Congr. Eur. Soc. Urol. Oncol. & Endocrinol., p. 233–247. Acta Medica, Rome 1984.

Labrie F. , Dupont A. , Belanger A. : New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LH-RH agonist. Hormone Res., 18; 18 (1983).

Schally A. W. , Arimura A. , Baba Y. : Isolation and properties of the FSH and LH releasing hormone. Biochem. Biophys. Res. Commun., 43; 393 (1971).

Hsueb A. J. W. , Erickson G. F. : Extra-pituitary inhibition of testicular function by luteinising hormone releasing hormone. Nature, 281; 66 (1979).

Wenderoth U. K. , Jacobi G. H. : Gonadotropin releasing hormone analogues for palliation of carcinoma of the prostate; a new approach to the classical concept. World J. Urol, 1; 40 (1983).

Walker K. J. , Nicholson R. I. , Turkes A. O. : Therapeutic potential of the LH-RH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet, 2; 413 (1983).

Ahmed S. R. , Brooman P. J. C. , Shalet S. M. : Treatment of advanced prostatic cancer with LH-RH analogue ICI 118630: Clinical response and hormonal mechanisms. Lancet, 2; 415 (1983).

Smith J. A. jr. : Androgen suppression by gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J. Urol., 131; 1110 (1984).

Kerle D. , Williams Gordon , Ware H. , Bloom S. R. : Failure of long term luteinizing hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Brit. Med. J., 289; 468 (1984).

Winfield H. , Trachtenberg J. : A comparison of a powerful luteinising hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J. Urol., 131; 1107 (1984).

Kerle D. , Williams Gordon , Ware H. : Experience with an LH-RH analogue in the management of relapsed progressive prostatic cancer. Brit. J. Urol., 56; 495 (1984).

Mahoney E. M. , Harrison H. : Bilateral adrenalectomy for palliative treatment of prostatic cancer. J. Urol., 108; 936 (1972).

Schmidt J. D. : Endocrine therapy for prostatic cancer. In: Murphy G. P. (ed.): Cancer of the prostate. Clinics in Oncology, vol. 2, n° 2, p. 357–370, W. B. Saunders, London 1983.

Robinson M. R. G. , Shearer R. J. , Fergusson J. D. : Adrenal suppression in the treatment of carcinoma of the prostate. Brit. J. Urol., 46; 555 (1974).

Worgul T. J. , Santen R. J. , Samojlik E. : Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J. Urol., 129; 51 (1983).

Smith J. A. jr. , Eyre H. J. , Roberts T. S. , Middleton R. G. : Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer, 53; 2385 (1984).

Mee A. D. , Khan O. , Mashiter K. : High serum prolactine associated with poor prognosis in carcinoma of the prostate. Brit. J. Urol., 56; 698 (1984).

Coune A. , Smith P. : Clinical trial of 2-bromoergocryptine (NSC 169774) in human prostatic cancer. Cancer Chemoter. Rep., 59; 209 (1975).

Trachtemberg J. : Ketoconazole therapy in advanced prostatic cancer. J. Urol., 132; 61 (1984).

Schumeyer Th. , Nieschlag E. : Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. Acta Endocrinol., 105; 275 (1984).

Pont A. , Williams P. L. , Loose D. S. : Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med., 97; 370 (1982).

Gordon W. , Allen J. M. , Kerle D. : Testicular and adrenal testosterone ablation using combined LH-RH analogue and ketoconazole for advanced progressive carcinoma of the prostate. A.U.A. 79^th Annual Meeting (Abstr. N° 423), loc. cit. (1984).

Tew K. D. , Hartley-Asp B. : Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology, 23 (suppl.); 28 (1984).

Forsgren B. , Bjork P. : Specific binding of estramustine to prostatic proteins. Urology, 23 (suppl.); 34 (1984).

Karr J. P. , Wajsman Z. , Kirdani R. Y. : Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J. Urol., 124; 232 (1980).

Hoisaeter P. A. , Bakke A. : Estramustine phosphate (estracyt): Experimental and clinical studies in Europe. Sem. Oncol., 10 (suppl. 3); 27 (1983).

Murphy G. P. , Slack N. H. , Mittelman A. : Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer. Sem. Oncol., 10 (suppl. 3); 34 (1983).

Benson R. C. jr. , Gill G. M. , Cummings K. B. : A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma. Sem. Oncol., 10 (suppl. 3); 43 (1983).

Nesbit R. M. , Baum W. C. : Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. J.A.M.A., 143; 1317 (1950).

Lepor H. , Ross A. , Walsh P. C. : The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol., 128; 335 (1982).

Murphy G. P. , National Prostatic Cancer Project Group: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer, 51; 1264 (1983).

Elder J. S. , Catalona W. J. : Management of newly diagnosed metastatic carcinoma of the prostate. Urol. Clin. N. Amer., 11; 283 (1984).

Reiner W. G. , Scott W. W. , Eggleston J. C. , Walsh P. C. : Long-term survival after hormonal therapy for stage D prostatic cancer. J. Urol., 122; 183 (1979).

Barnes R. W. , Ninan C. A. : Carcinoma of the prostate: biopsy and conservative therapy. J. Urol., 108; 897 (1972).

Byar D. P. , Veterans Administration Cooperative Urplogical Research Group: Survival of patients with incidentally found microscopic cancer of the prostate: results of a cilnical trial of conservative treatment. J. Urol., 108; 908 (1972).

Heaney J. A. , Chang H. C. , Daly J. J. , Prout G. R. jr. : Prognosis of clinically undiagnosed prostatic carcinoma and the influence of endocrine theraphy. J. Urol., 118; 283 (1977).

Barnes R. , Hirst A. , Rosenquist R. : Eearly carcinoma of the prostate: comparison of stages A and B. J. Urol., 115; 404 (1976).

Scott W. W. , Boyd H. L. : Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J. Urol., 101; 86 (1969).

Paulson D. F. , Hodge G. B. jr. , Hinshaw W. , Uro-Oncology Research Group: Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J. Urol., 131; 901 (1984).

Paulson D. F. , Cline W. A. jr. , Koefoot R. B. , Uro-Oncology Research Group: Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. J. Urol., 127; 935 (1982).

Slack N. H. , Murphy G. P. , Participants in the National Prostatic Cancer Project: Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol. Clin. N. Amer., 11; 337 (1984).

Stone A. R. , Hargreave T. B. , Chisholm G. D. : The diagnosis of estrogen escape and the role of secondary orchiectomy in prostatic cancer. Brit. J. Urol., 52; 535 (1980).

McFarlane J. R. , Tolley D. A. : Flutamide therapy for advanced prostatic cancer: a phase II study. Brit. J. Urol., 57; 172 (1985).

Prout G. R. jr. , Kliman B. , Daly J. J. : In vitro uptake of ³H-testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues. J. Urol., 116; 603 (1976).

Kliman B. , Prout G. R. jr. , McLaughlin R. A. : Altered androgen metabolism in metastatic prostate cancer. J. Urol., 119; 623 (1978).

Labrie F. : A new approach in the hormonal treatment of prostatic cancer: complete instead of partial blockade of androgens. Intern. J. Androl., 7; 1 (1984).

Labrie F. , Belanger A. , Dupont A. : Combined treatment with LH-RH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet, 8411; 1090 (1984).

Buttyan R. , Olsson C. A. : Androgenic receptor assays in advanced prostatic cancer. Urol. Clin. N. Amer., 11; 311 (1984).

De Sombre E. R. , Carbone P. P. , Jensen E. V. : Steroid receptors in breast cancer. N. Engl. J. Med., 18; 1011 (1979).

Chung L. W. K. , Thompson T. C. , Rocco A. K. : Role of androgen receptors in stromal-epithelial interactions in prostate cancer. In: Ratcliff T. L. , Catalona W. J. : Urologic Oncology, p. 17–38, Martinus Nijhoff Publ., Boston 1984.

Ekman P. , Barrack E. R. , Walsh P. C. : Simultaneous measurements of progesterone and androgen receptors in human prostate: a microassay. J. Clin. Endocrinol. Metab., 55; 1089 (1982).

Wagner R. K. , Schultze K. H. : Clinical relevance of androgen receptor content in human prostate carcinoma. Acta Endocrinol., 215 (suppl.); 139 (1978).

Mobbs B. G. , Johnson I. E. , Connolly J. G. , Clark A. F. : Androgen receptor assay in human benign and malignant prostate tumor cystosol using protamine sulfate precipitation. J. Steroid Biochem., 9; 289 (1978).

De Voogt H. J. , Dingjan P. : Steroid receptors in human prostate cancer. Urol. Res., 6; 151 (1978).

Gustafsson J. A. , Ekman P. , Snochowski M. : Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer. Cancer Res.. 38; 4345 (1978).

Ekman P. , Snochowski M. , Zetterberg A. : Steroid receptor content in humsn prostatic carcinoma and response to endocrine therapy. Cancer, 44; 1173 (1979).

Martelli A. , Soli M. , Bercovich E. : Correlation between clinical response to antiandrogenic therapy and occurrence of receptors in human prostatic cancer. Urology, 16; 245 (1980).

Ghanadian R. , Auf G. , Williams G. : Predicting the response of prostatic carcinoma to endocrine therapy. Lancet, 2; 1418 (1981).

Trachtenberg J. , Walsh P. C. : Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J. Urol., 127; 466 (1982).

Concolino C. , Marocchi A. , Margiotto G. : Steroid receptors and hormone responsiveness of human prostatic carcinoma. Prostate, 3; 475 (1982).

Barrack E. R. , Bujnovszky P. , Walsh P. C. : Subcellular distribution of androgen receptors in human normal, benign hyperplastic and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res., 43; 1107 (1983).

Gonor S. E. , Lakey W. H. , McBlain W. A. , Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J. Urol., 131; 1196 (1984).

Ekman P. , Snochowski M. , Dahlberg E. , Gustafsson J. A. : Steroid receptors in metastatic carcinoma of the human prostate. Europ. J. Cancer, 15; 257 (1979).

Bartsch G. , Rohr H. P. : Ultrastructural stereology. A new approach to the study of prostatic function. Invest. Urol., 14; 301 (1977).

Berns E. M. J. J. , Blankenstein R. A. , De Goey T. F. P. M. : Fluorescent ligands do not discriminate between androgen receptor and/or estrogen receptor — positive and — negative human tumour cells. In: Bracci U., Di Silverio F. (eds.), op. cit., p. 15–25 (1984).

Pertschuk L. P. , Macchia R. J. , New York Prostate Cancer Binding Site Study Group: Histochemical androgen binding assay in prostatic cancer. J. Urol., 131; 1096 (1984).

Pertschuk L. P. , Macchia R. J. , Eisemberg K. B. : Fluorescence studies of steroid binding sites in prostatic cancer. In: Bracci U., Di Silverio F. (eds.), op. cit., p. 1–13 (1984).

Green G. L. , Nolan C. , Engler J. P. , Jensen E. V. : Monoclonal antibodies to human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A., 77; 5115 (1980).

Geller J. , Albert J. , Loza D. : DHT concentrations in human prostatic cancer tissue. J. Clin. Endocrinol. Metab., 46; 440 (1978).

Geller J. , Albert J. , De La Vega D. : Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormone dependency. Cancer Res., 38; 4349 (1978).

Geller J. , Albert J. , Nachtsheim D. A. , Loza D. : Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J. Urol., 132; 693 (1984).

Brendler C. B. , Isaacs J. T. , Follansbee A. L. , Walsh P. C. : The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J. Urol., 131; 694 (1984).